Mirati Therapeutics, Inc. (NasdaqGS: MRTX) Loss Submission Form

Kuznicki Law is investigating the proposed sale of Mirati Therapeutics, Inc. (NasdaqGS: MRTX) to Bristol-Myers Squibb Company (NYSE: BMY).  Under the terms of the proposed transaction, shareholders of Mirati will receive $58.00 in cash for each share of Mirati that they own as well as one non-tradeable Contingent Value Right per Mirati share, entitling its holder to receive a one-time potential payment of $12.00 in cash upon acceptance by U.S. FDA of a new drug application for MRTX1719 for the treatment of either locally advanced or metastatic NSCLC in patients who have received no more than two prior lines of systemic therapy within seven years after the closing of the merger. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.